Molecular Cancer Research · 2004 · 57 citations · 47 references
PharmacyImmunologyMolecular PharmaceuticsOcular Drug DeliveryOcular ImmunologyTumor MicroenvironmentAngiogenesisCorneal Drug DeliveryCorneal VascularizationCytokine-based TherapyIntegrin SignalingTumor Microenvironment ModulationAngiogenic CytokinesCorneal AngiogenesisImmunofluorescence AssaysIntegrin ReceptorsIntegrin-binding LigandsIntegrin-mediated AngiogenesisPeptide Delivery SystemsPeptide-mediated Delivery
Abstract We engineered a fusion protein, mrIL-12vp [mouse recombinant interleukin (IL)-12 linked to vascular peptide], linking the vascular homing peptide CDCRGDCFC (RGD-4C), a ligand for αvβ3 integrin, to mrIL-12 to target IL-12 directly to tumor neovasculature. The fusion protein stimulated IFN-γ production in vitro and in vivo, indicating its biological activity was consistent with mrIL-12. Immunofluorescence techniques showed mrIL-12vp specifically bound to αvβ3 integrin-positive cells but not to αvβ3 integrin-negative cells. In corneal angiogenesis assays using BALB/c mice treated with either 0.5 μg/mouse/d of mrIL-12vp or mrIL-12 delivered by subcutaneous continuous infusion, mrIL-12vp inhibited corneal neovascularization by 67% compared with only a slight reduction (13%) in angiogenesis in the mrIL-12-treated animals (P = 0.008). IL-12 receptor knockout mice given mrIL-12vp showed a marked decrease in the area of corneal neovascularization compared with mice treated with mrIL-12. These results indicate that mrIL-12vp inhibits angiogenesis through IL-12-dependent and IL-12-independent mechanisms, and its augmented antiangiogenic activity may be due to suppression of endothelial cell signaling pathways by the RGD-4C portion of the fusion protein. Mice injected with NXS2 neuroblastoma cells and treated with mrIL-12vp showed significant suppression of tumor growth compared with mice treated with mrIL-12 (P = 0.03). Mice did not show signs of IL-12 toxicity when treated with mrIL-12vp, although hepatic necrosis was present in mrIL-12-treated mice. Localization of IL-12 to neovasculature significantly enhances the antiangiogenic effect, augments antitumor activity, and decreases toxicity of IL-12, offering a promising strategy for expanding development of IL-12 for treatment of cancer patients.
47
Hans-Peter Gerber, Amy E. McMurtrey, Joe Kowalski et al. · Journal of Biological Chemistry · 1998 · 2K citations · Full text
Michiko Kobayashi, Lori Fitz, Michael P. Ryan et al. · The Journal of Experimental Medicine · 1989 · 2K citations · Full text